This announcement is a separate document:
艾迪药业董事会关于公司本次重大资产重组符合《科创板上市公司持续监管办法（试行）》第二十条、《上海证券交易所上市公司重大资产重组审核规则》第八条、《上海证券交易所科创板股票上市规则》第11.2条规定的说
The board of directors of Jiangsu Aidea Pharmaceutical Co., Ltd. stated that this major asset restructuring complies with Article 20 of the Continuous Supervision Measures for Listed Companies on the Science and Technology Innovation Board (Trial), Article 8 of the Shanghai Stock Exchange's Review Rules for Major Asset Restructuring of Listed Companies, and Article 11.2 of the Listing Rules for Stocks on the Science and Technology Innovation Board of Shanghai Stock Exchange.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.